Feedback activation of GATA1/miR-885-5p/PLIN3 pathway decreases sunitinib sensitivity in clear cell renal cell carcinoma

References

• Huang Y, Wang J, Jia P, et al. Clonal architectures predict clinical outcome in clear cell renal cell carcinoma. Nat Commun. 2019;10:1245.
   PubMed Web of Science ®Google Scholar
• Hakimi AA, Reznik E, Lee CH, et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell. 2016;29:104–116.
   PubMed Web of Science ®Google Scholar
• Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15:55–64.
   PubMed Web of Science ®Google Scholar
• Sanchez DJ, Simon MC. Transcriptional control of kidney cancer. Science. 2018;361:226–227.
   PubMed Web of Science ®Google Scholar
• Yao X, Tan J, Lim KJ, et al. VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discov. 2017;7:1284–1305.
   PubMed Web of Science ®Google Scholar
• Hall DP, Cost NG, Hegde S, et al. TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma. Cancer Cell. 2014;26:738–753.
   PubMed Web of Science ®Google Scholar
• Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10:757–763.
   PubMed Web of Science ®Google Scholar
• Ornstein MC, Wood LS, Elson P, et al. A phase II study of intermittent sunitinib in previously untreated patients with metastatic renal cell carcinoma. J clin oncol. 2017;35:1764–1769.
   PubMedGoogle Scholar
• Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516–2524.
   PubMed Web of Science ®Google Scholar
• Polyzos A. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J Steroid Biochem Mol Biol. 2008;108:261–266.
   PubMed Web of Science ®Google Scholar
• Barrios CH, Hernandez-Barajas D, Brown MP, et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer. 2012;118:1252–1259.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–3590.
   PubMed Web of Science ®Google Scholar
• Morais C. Sunitinib resistance in renal cell carcinoma. J Kidney Cancer VHL. 2014;1:1–11.
   PubMedGoogle Scholar
• Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10:992–1000.
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592–603.
   PubMed Web of Science ®Google Scholar
• Pisarsky L, Bill R, Fagiani E, et al. Targeting metabolic symbiosis to overcome resistance to anti-angiogenic therapy. Cell Rep. 2016;15:1161–1174.
   PubMed Web of Science ®Google Scholar
• Selbach M, Schwanhausser B, Thierfelder N, et al. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455:58–63.
   PubMed Web of Science ®Google Scholar
• Yamaguchi N, Osaki M, Onuma K, et al. Identification of MicroRNAs involved in resistance to sunitinib in renal cell carcinoma cells. Anticancer Res. 2017;37:2985–2992.
   PubMed Web of Science ®Google Scholar
• Prior C, Perez-Gracia JL, Garcia-Donas J, et al. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One. 2014;9:e86263.
   PubMed Web of Science ®Google Scholar
• Gamez-Pozo A, Anton-Aparicio LM, Bayona C, et al. MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia. 2012;14:1144–1152.
   PubMed Web of Science ®Google Scholar
• Tombol Z, Eder K, Kovacs A, et al. MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas. Mod Pathol. 2010;23:1583–1595.
   PubMed Web of Science ®Google Scholar
• Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007;4:721–726.
   PubMed Web of Science ®Google Scholar
• Bulankina AV, Deggerich A, Wenzel D, et al. TIP47 functions in the biogenesis of lipid droplets. J Cell Biol. 2009;185:641–655.
   PubMed Web of Science ®Google Scholar
• Li Y, Bai H, Zhang Z, et al. The up-regulation of miR-199b-5p in erythroid differentiation is associated with GATA-1 and NF-E2. Mol Cells. 2014;37:213–219.
   PubMed Web of Science ®Google Scholar
• Dore LC, Amigo JD, Dos Santos CO, et al. A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc Nat Acad Sci. 2008;105:3333–3338.
   PubMed Web of Science ®Google Scholar
• Liu Y, Bao Z, Tian W, et al. miR-885-5p suppresses osteosarcoma proliferation, migration and invasion through regulation of beta-catenin. Oncol Lett. 2019;17:1996–2004.
   PubMed Web of Science ®Google Scholar
• Jin X, Wang Z, Pang W, et al. Upregulated hsa_circ_0004458 contributes to progression of papillary thyroid carcinoma by inhibition of miR-885-5p and activation of RAC1. Med Sci Monit. 2018;24:5488–5500.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yin J, Yang J, et al. miR-885-5p suppresses hepatocellular carcinoma metastasis and inhibits Wnt/beta-catenin signaling pathway. Oncotarget. 2016;7:75038–75051.
   PubMedGoogle Scholar
• Afanasyeva EA, Mestdagh P, Kumps C, et al. MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. Cell Death Differ. 2011;18:974–984.
   PubMed Web of Science ®Google Scholar
• Lam CSC, Ng L, Chow AKM, et al. Identification of microRNA 885-5p as a novel regulator of tumor metastasis by targeting CPEB2 in colorectal cancer. Oncotarget. 2017;8:26858–26870.
   PubMedGoogle Scholar
• Gui JH, Tian YP, Wen XY, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci. 2011;120:183–193.
   PubMed Web of Science ®Google Scholar
• Raitoharju E, Seppala I, Lyytikainen LP, et al. Blood hsa-miR-122-5p and hsa-miR-885-5p levels associate with fatty liver and related lipoprotein metabolism-the young finns study. Sci Rep. 2016;6:38262.
   PubMed Web of Science ®Google Scholar
• Yang W, Hood BL, Chadwick SL, et al. Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. Hepatology. 2008;48:1396–1403.
   PubMed Web of Science ®Google Scholar
• Hakimi AA, Pham CG, Hsieh JJ. A clear picture of renal cell carcinoma. Nat Genet. 2013;45:849–850.
   PubMed Web of Science ®Google Scholar
• Sounni NE, Cimino J, Blacher S, et al. Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell Metab. 2014;20:280–294.
   PubMed Web of Science ®Google Scholar
• Ferguson D, Zhang J, Davis MA, et al. The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus-driven hepatic steatosis. J Lipid Res. 2017;58:420–432.
   PubMed Web of Science ®Google Scholar
• Wang K, Ruan H, Song Z, et al. PLIN3 is up-regulated and correlates with poor prognosis in clear cell renal cell carcinoma. Urol Oncol. 2018;36(343):e9–e19. .
   Google Scholar
• Jackson CL. Lipid droplet biogenesis. Curr Opin Cell Biol. 2019;59:88–96.
   PubMed Web of Science ®Google Scholar
• Petan T, Jarc E, Jusovic M. Lipid droplets in cancer: guardians of fat in a stressful world. Molecules. 2018;23:E1941.
   PubMed Web of Science ®Google Scholar
• Frew IJ, Moch H. A clearer view of the molecular complexity of clear cell renal cell carcinoma. Annu Rev Pathol. 2015;10:263–289.
   PubMed Web of Science ®Google Scholar
• Qiu B, Ackerman D, Sanchez DJ, et al. HIF2alpha-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma. Cancer Discov. 2015;5:652–667.
   PubMed Web of Science ®Google Scholar
• Ackerman D, Tumanov S, Qiu B, et al. Triglycerides promote lipid homeostasis during hypoxic stress by balancing fatty acid saturation. Cell Rep. 2018;24:2596–2605.
   PubMed Web of Science ®Google Scholar
• Liu Q, Luo Q, Halim A, et al. Targeting lipid metabolism of cancer cells: A promising therapeutic strategy for cancer. Cancer Lett. 2017;401:39–45.
   PubMed Web of Science ®Google Scholar